Micolysin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Micolysin

Property Description
Active ingredient Clotrimazole
Form Topical Solution (or Cream/Lotion)
Pharmacological class Antifungal Agent, Imidazole Derivative
Common use General Mycoses (Fungal Infections)
Origin Synthetic Compound

The Core Identity of Micolysin: Definition and Composition

Micolysin is an established synthetic medication defined by its active chemical substance, Clotrimazole (INN). The drug is classified within the azole antifungal family, belonging specifically to the imidazole derivative group. Clotrimazole is globally and clinically recognized for its effectiveness against superficial fungal infections.

This classification establishes Micolysin as a dedicated, focused antimycotic agent. Clotrimazole is a cornerstone treatment, emphasizing its therapeutic importance for public health. The compound is recognized for its broad-spectrum action against various fungal species.

Physical Form and General Therapeutic Purpose

Micolysin is commonly formulated as a topical solution or cream, which necessitates its use via the cutaneous route of administration—external application directly to the skin or affected area. Its composition is focused: the active ingredient, Clotrimazole, is combined with a suitable vehicle (such as an alcoholic or oily base) to ensure proper stability and spreadability across the target tissue.

The essential purpose of this product is to serve as a broad-spectrum antifungal, addressing a range of mycoses caused by common fungi and yeasts. Clotrimazole’s primary therapeutic role is to clear the fungal growth and prevent its spread in affected external areas, a goal achieved through highly localized delivery. The medication is often used to resolve localized fungal conditions that benefit from direct application, a clear differentiation from oral treatments.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Micolysin?

Possible Side Effects and Safety Information

The safety profile of Micolysin (Clotrimazole topical) primarily relates to effects observed at the site of application, reflecting its low systemic absorption. The potential adverse reactions are officially classified based on their frequency in clinical use, according to major government regulatory documents.

Adverse Reaction Classifications

The most frequently reported effects are classified as common and include localized reactions such as a burning sensation, pruritus (itching), and irritation. These effects are generally transient, and regulatory sources note that a mild, temporary burning sensation may be more frequently observed at the beginning of treatment.

Less frequently reported (uncommon) effects involve further application site reactions such as pain, oedema (swelling), and erythema (redness).

Serious Reactions and Safety Constraints

Serious adverse reactions, though rare for topical formulations, are documented and include hypersensitivity reactions, such as anaphylaxis and angioedema. Systemic events like syncope (fainting) or hypotension (low blood pressure) have also been recorded.

Safety constraints include the contraindication of the medicine in individuals with a known hypersensitivity to the active ingredient, Clotrimazole, or to any of the non-active excipients. Furthermore, the use of certain Clotrimazole formulations in the genital area may reduce the effectiveness of latex contraceptives (condoms or diaphragms) upon co-application.

Overdose and Emergency Response

Overdose and When to Seek Help

This section summarizes the official regulatory information regarding overdosage, based on authoritative government-authorized prescribing documents (FDA, EMA, etc.) for Micolysin-class antifungal agents.

Overdosage is primarily addressed in the context of accidental oral ingestion, rather than overuse via the intended topical or vaginal route. Due to the minimal systemic absorption of the active ingredient from topical or vaginal application, an acute toxic systemic reaction is generally not expected, even with the application of an overdose.

Documented Overdose Presentations

Overdose Circumstance Documented Manifestations
Accidental Oral Ingestion Harmful if swallowed; symptoms may include dizziness, headache, and nausea.
Excessive Topical/Vaginal Use Acute systemic intoxication is generally not expected.

Emergency Actions and Required Medical Attention

In the event of accidental oral ingestion, official labeling requires immediate action and urgent consultation. The substance is classified as harmful if swallowed, and medical help must be sought immediately. Management is symptomatic and supportive. Procedural instructions include rinsing the mouth, and it is explicitly stated not to induce vomiting unless directed to do so by a healthcare professional or Poison Control Center.

There is no specific antidote for Micolysin overdose documented in official regulatory sources.

Therapeutic Uses of Micolysin

What Micolysin Treats: Main Uses and Benefits

The core therapeutic domain for a product like Micolysin is the management of symptoms related to inflammatory or irritative states caused by fungal (mycotic) infections. This product, which belongs to the imidazole class of antifungal medications, is applied in addressing conditions involving episodic or fluctuating manifestations across cutaneous (skin) and mucosal areas. This is often used during phases when symptoms become more noticeable.

The topical application of this medication is commonly used to help with symptoms related to physical discomfort in conditions such as tinea corporis (ringworm), tinea cruris (jock itch), and tinea pedis (athlete's foot). It may also be part of symptomatic management for other fungal or yeast infections of the skin. The use of this treatment is relevant when supportive symptom management is appropriate, as it contributes to easing the overall symptom load.

The use of this treatment is considered relevant for easing discomfort linked to these conditions: it may provide support that helps ease the overall symptom burden during these periods. This assistance may contribute to maintaining a sense of stability when symptoms are more noticeable, which may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Itching and Scaling

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Micolysin — Official Regulatory Information

Eligibility Scope

Classification Population/Condition Regulatory Status
Absolute Contraindication Hypersensitivity Must not use if allergic to clotrimazole or any excipient in the formulation.
Pediatric Restriction Children under 2 years of age Not recommended for self-medication; use is only permitted under medical advice.
Anatomical Restriction Eye, Scalp, or Nails Not for use; the topical formula is strictly for external skin application and is not effective for these sites.
Pregnancy/Lactation First Trimester Not recommended due to limited safety data.
Lactation Breastfeeding Use with caution; the product should not be applied to the breast area.

Condition-Specific Eligibility

For the topical formulation, no specific restrictions or dose adjustments are typically required for individuals with existing hepatic (liver) or renal (kidney) impairment. This is an eligibility statement related to the negligible systemic absorption of the drug.


Resulting Eligibility Structure

Official regulatory documents define eligibility through a universal hypersensitivity contraindication and specific age-based limitations for the very young. The profile is largely defined by its topical route: it is contraindicated for internal or ophthalmic use, and use is not established for nail or scalp infections. General use is allowed for the adult population, subject to caution regarding pregnancy and lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes drug interactions documented in regulatory labeling for Micolysin (Clotrimazole), focusing on systemic risk, even with minimal absorption from topical use.


The primary mechanism of interaction is the inhibition of Cytochrome P450 enzymes, mainly CYP3A4 and CYP2C9, which can reduce the metabolism and increase the plasma concentrations of co-administered drugs. This pharmacokinetic effect dictates the most significant interaction constraints.

Clinically Significant Interactions

Interacting Product Category Consequence and Constraint
Oral Anticoagulants (e.g., Warfarin) Increased risk of bleeding due to elevated anticoagulant exposure; necessitates mandatory monitoring of International Normalized Ratio (INR).
Immunosuppressants (e.g., Tacrolimus, Sirolimus) Increased plasma concentrations of the immunosuppressant; requires close monitoring of drug levels.
Latex Contraceptives (e.g., condoms, diaphragms) Reduced efficacy of latex products when used with vaginal formulations; alternative non-latex precautions must be used for at least five days after treatment.
CYP3A4 Substrates (e.g., certain Statins) Increased risk of toxicity; contraindicated in the context of systemic exposure for high-risk substrates.

The official interaction profile requires specific restrictions to manage both systemic and local risks. Patients with hepatic impairment may be more susceptible to potential systemic consequences and require careful consideration.

Mechanism of Action

How Micolysin Works

Micolysin exerts its action through a mechanism that targets the cellular integrity and metabolic viability of fungal organisms. This action is rooted in two primary mechanistic domains:

Inhibition of Fungal Sterol Synthesis

The drug's core molecular function is to inhibit the fungal enzyme lanosterol 14-alpha-demethylase (CYP51). This enzyme is critical for the ergosterol biosynthesis pathway, which creates the necessary lipid (ergosterol) for the fungal cell membrane. By blocking this pathway, Micolysin simultaneously starves the cell of its primary structural component and causes the buildup of toxic, faulty sterol precursors.

Disruption of Fungal Cell Membrane Structure

The resulting presence of faulty sterols leads to a profound structural and functional disruption of the cell membrane. This damage increases the membrane’s permeability, causing critical internal components like ions and nutrients to leak out. This loss of cellular homeostasis progresses to either the cessation of fungal growth (fungistatic action) or, at sufficient concentration, the direct physical destruction of the cell (fungicidal action). This mechanism of fungal inhibition and cell death is the direct cause of the drug’s pharmacodynamic action.

Dosage and Administration Information

How to Use Micolysin: Official Administration Guidelines

The usage of Micolysin (Clotrimazole 1% topical preparations) is defined by official administration instructions to ensure proper application and course completion. These guidelines establish the high-level protocol for its use, strictly focusing on procedural requirements and labeled dosing.


Administration Scope

Feature Guideline
Route of administration Topical (Cutaneous) application only.
Dosing schedule Apply a thin layer of the 1% preparation to the entire affected area and surrounding skin.
Age-group rules The standard regimen applies to individuals 2 years of age and older. Use in children under 2 years requires specific professional guidance.
Missed-dose rules If an application is missed, it should be applied as soon as it is remembered, then the regular schedule should be resumed.

Instruction Classifications

Classification Principle
Administration method type Topical (External use only).
Frequency pattern Twice daily (Divided use, typically morning and evening).
Use-context constraints Not indicated for lesions of the scalp or nails.

Resulting Procedural Structure

Official step sequence:

  • Cleanse and thoroughly dry the affected skin area before each application.
  • Apply a sufficient, thin layer of the preparation to the lesion and the skin immediately surrounding it.
  • Gently massage the preparation into the skin until the application is complete.
  • Maintain the application regimen twice daily for the full prescribed duration (e.g., 2 weeks for tinea cruris or 4 weeks for tinea pedis).

Connection to the overall use protocol: The official instructions establish a standardized topical administration protocol that defines the application frequency and the minimum required duration for specific conditions. These requirements ensure consistent procedural adherence, such as applying the thin layer twice daily to clean, dry skin. The full duration must be completed regardless of prior symptomatic improvement.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Micolysin (Topical Clotrimazole)

This overview summarizes the available research concerning the use of Micolysin (Clotrimazole) for common fungal skin conditions. It explains what types of studies have been performed, what the researchers monitored, and what aspects of the evidence are still being explored.


Evidence for use in Ringworm (Tinea Corporis) and Jock Itch (Tinea Cruris)

Research on Micolysin for ringworm and jock itch was evaluated in short-term randomized controlled trials (RCTs). These studies primarily examined fungal clearance, a lab measurement known as mycological cure, and monitored physical signs like redness (erythema), scaling, and patient-reported itching (pruritus). Research so far describes patterns where, following the full course of application studied, some patient groups showed lab findings consistent with mycological clearance. This evidence was observed in research contexts involving fluctuating or unstable symptoms within the specific time intervals observed in the trials.

Evidence for use in Athlete's Foot (Tinea Pedis)

Studies for athlete's foot was evaluated in RCTs, many of which were conducted in comparative settings against an inactive substance (placebo) or other antifungal agents. Researchers examined whether laboratory tests could confirm the absence of the fungus and measured the resolution of observable symptoms like fissuring, scaling, and inflammation. Trials reported patterns indicating that mycological clearance rates observed in the Micolysin groups differed from those measured in the placebo groups. Comparative studies exploring newer topical agents reported that those agents were observed in some studies to reach certain endpoints sooner, though the final clearance measurements were often comparable.

Long-term Follow-up and Durability of Response

Research exploring the findings of Micolysin was observed in studies over a defined time interval—usually 2 to 4 weeks of treatment, with final checks 1 to 4 weeks after the application ended. This means that follow-up durations were limited. There is limited information for long-term outcomes regarding how often infections may recur months after the final application. The certainty remains low regarding relapse rates, as studies were not typically designed to monitor patients over six months or a year.

What is Still Uncertain About Micolysin Research

While research contributes to the broader evidence landscape, several limitations have been identified. Long-term effects are not fully established, and data for certain groups remain insufficient. This includes limited research on specific underlying medical conditions, such as immunocompromised states or diabetes. The extent to which real-world compliance influences the findings reported in these studies appears to be a continuing area where more research and observational data are needed. Research provides context but not individual predictions.

Key Studies & References

  1. Clotrimazole: Clinical Pharmacology. In: StatPearls.
  2. Clotrimazole Topical. MedlinePlus Drug Information
  3. Topical antifungal therapy for cutaneous candidiasis and dermatophytosis

Frequently Asked Questions (FAQ)

Common questions about Micolysin (FAQ)


Q: How quickly does Micolysin typically start to have an effect?

Official product information does not specify an exact time for the onset of symptomatic relief with Micolysin. Regulatory documents state that patients may be advised to consult a healthcare professional if improvement is not observed after completing the specified course of treatment, which typically ranges from two to four weeks.


Q: Are there foods or drinks that should be avoided while taking Micolysin?

Official drug labeling for Micolysin topical formulations generally does not list specific interactions with common foods or drinks. This is consistent with the product's established minimal absorption into the bloodstream. Official guidance indicates the importance of reviewing a complete medical history and all consumed products with a healthcare provider.


Q: Is it normal to feel slightly dizzy when first starting Micolysin?

Official safety information indicates that the most commonly reported effects of Micolysin are localized to the application site, such as a temporary burning sensation or itching. Systemic effects like dizziness are generally not listed as frequent with the topical formulation, though some regulatory documents mention fainting or dizziness as potential rare systemic events.


Q: Does Micolysin interact with common pain relievers like ibuprofen?

Regulatory labeling for topical Micolysin does not typically list specific interactions with common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. The primary interaction warnings focus on high-risk oral drugs that are known to be metabolized by certain liver enzymes that Micolysin may affect.


Q: What does the term 'Micolysin resistance' mean in simple terms?

Fungal resistance is an occurrence where the organism being treated no longer responds to the drug's mechanism of action, preventing the drug from being effective. Official regulatory documents describe this event as rare for Micolysin. It is a factor considered during the clinical review of treatment response.


Q: Is Micolysin available over the counter in some countries?

Yes, the topical formulation of Micolysin containing Clotrimazole 1% is widely defined in regulatory documents as an Over-The-Counter (OTC) product. This classification means it is generally available for purchase without a prescription, though specific access rules may vary regionally.


Q: Can Micolysin affect the results of a routine blood test?

Official information does not indicate that Micolysin generally interferes with the results of routine blood tests. However, regulatory guidance suggests that if a patient does not respond to the treatment, microbiological studies may be repeated to confirm the diagnosis or rule out other causes of infection.


Q: What should I do if I accidentally take two Micolysin tablets instead of one?

Micolysin is intended for external application only, and official labeling explicitly addresses ingestion. Official labeling for ingested product states that contact with a Poison Control Center or professional medical assistance service should be sought immediately.


Q: Is Micolysin considered a controlled substance?

Micolysin is not classified as a controlled substance by regulatory bodies like the Drug Enforcement Administration (DEA). This status confirms that the drug has not been determined to have a risk of dependence or addiction.


Q: Are there any known interactions between Micolysin and herbal supplements?

Regulatory documents describe the importance of disclosing all products used, including herbal supplements and vitamins, to a healthcare provider. While specific interactions with herbal products are typically not listed for the topical formulation, this ensures comprehensive health awareness.


Q: Does Micolysin interact with alcohol?

Specific warnings regarding an interaction between topical Micolysin and consumed alcohol are generally not included in the official labeling. This is consistent with the drug's minimal systemic absorption into the body.


Q: What is the risk of dependence or addiction with Micolysin?

Regulatory documents indicate that Micolysin has not been determined to have a risk of dependence or addiction. This drug is not included in the schedules for controlled substances maintained by government drug regulatory agencies.


Q: Is there a generic version of Micolysin available?

Yes, the active ingredient in Micolysin, Clotrimazole 1%, is available in generic topical forms such as creams, solutions, and lotions. Regulatory documents show that the product is widely distributed by multiple manufacturers under its generic name.


Q: What is the proper way to discontinue Micolysin treatment?

Official regulatory guidance emphasizes that the medication is intended to be used for the full course of treatment indicated for the condition. It is noted that the course of treatment, typically two to four weeks, is intended to be completed regardless of prior symptomatic improvement.


Q: Can Micolysin affect vision or cause blurred sight?

Regulatory documents explicitly warn patients to avoid contact with the eyes when applying Micolysin. Although rare for topical use, some official safety profiles mention blurred vision as a potential systemic effect, emphasizing the need to keep the medication away from mucous membranes.


Q: What should I tell my doctor about before starting Micolysin?

Official patient information describes that a review of several factors with a healthcare provider is generally recommended before starting Micolysin. These include any known history of hypersensitivity (allergy) to any of the ingredients and a list of all other prescription or non-prescription products currently being used.


Q: Can Micolysin be used with certain vitamins?

Regulatory documents indicate that patients should disclose all products they are using, including vitamins and minerals, to their healthcare provider. Generally, there are no known direct interactions between the topical formulation of Micolysin and common vitamins.

How should Micolysin be stored and disposed of?

How to Store and Dispose of Micolysin

Official regulatory information requires that Micolysin (Clotrimazole Topical) be stored at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original container, which should be tightly closed when not in use.

Required Storage and Handling

  • Environmental Protection: The medicine must be protected from light, moisture, and excessive heat, and must not be allowed to freeze.
  • Child Safety: Micolysin must be stored out of the reach and sight of children to prevent accidental exposure.

Disposal Instructions

Unused or expired medicine should be properly discarded. Disposal is primarily handled through a drug take-back program. If one is unavailable, the product should be mixed with an undesirable substance (e.g., dirt) and sealed in a bag for disposal in the household trash. Do not flush Micolysin down a toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Micolysin found in:

A-Z Index: